Gregory Engel, MD
Clinical Cardiac Electrophysiology · E Palo Alto, CANPI 1467409763
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 88.5% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $46,489, more than ten times the $3,028 reported in 2019.
Across 402 payments — averaging $261.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$93K
- Abbott$5K
- Boston Scientific$2K
- Atricure, Inc.$974
- Amgen$471
- Impulse Dynamics (USA) Inc.$401
- plus $3K from 17 others
Across 36 payments — averaging $4270.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$135K
- Boston Scientific$19K
What the payments were for
- Consulting fees$10,31310%
- Speaking & faculty fees$60,20257%
- Travel & lodging$18,89818%
- Food & beverage$15,47015%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 211 | $92,911 |
| Abbott | 35 | $5,444 |
| Boston Scientific | 31 | $2,157 |
| Atricure, Inc. | 9 | $974 |
| Amgen | 18 | $471 |
| Impulse Dynamics (USA) Inc. | 2 | $401 |
| Biosense Webster, Inc. | 4 | $355 |
| E.r. Squibb & Sons, L.L.C. | 13 | $346 |
| Ablacon, Inc. | 2 | $331 |
| Sanofi-aventis U.S. LLC | 13 | $257 |
| Johnson & Johnson | 17 | $249 |
| Biotronik Inc. | 2 | $215 |
| Boehringer Ingelheim | 15 | $154 |
| AstraZeneca | 9 | $147 |
| Pfizer | 7 | $141 |
| Shockwave Medical, Inc | 4 | $105 |
| W. L. Gore & Associates, Inc. | 1 | $98 |
| Regeneron Healthcare Solutions, Inc. | 3 | $87 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Cardiva Medical, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $24 |
| Novartis | 1 | $19 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AURORA EV-ICD MRI SURESCAN$5,694
- EVERA MRI XT DR SURESCAN$4,773
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$3,080
- ENSITE$933
- Micra$826
- OPTIMIZER$802
- CROME DR MRI SURESCAN$756
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$704
- ENSITE PRECISION$394
- Rhythmia Mapping System$316
- Ensite Cardiac Mapping System$301
- SelectSecure$278
- Carto 3$265
- SYNERGY ABLATION SYSTEM$186
- EnSite Precision Cardiac Mapping System$170
- WATCHMAN FLX$144
- Farapulse$137
- CAMZYOS$131
- AFFERA MAPPING SYSTEM$100
How this compares
$104,961 in reported general payments places this provider in the 80th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 612 | $762,577 |
| JardianceEmpagliflozin | 109 | $123,569 |
| EntrestoSacubitril/Valsartan | 76 | $99,385 |
| XareltoRivaroxaban | 91 | $98,644 |
| MultaqDronedarone Hcl | 26 | $43,501 |
| Repatha SureclickEvolocumab | 29 | $41,323 |
| Dofetilide | 46 | $14,701 |
| Praluent PenAlirocumab | 15 | $9,872 |
| Metoprolol Succinate | 424 | $6,148 |
| Atorvastatin Calcium | 539 | $5,640 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 132 | $4,938 |
| Losartan Potassium | 337 | $4,290 |
| Rosuvastatin Calcium | 219 | $3,671 |
| Ezetimibe | 74 | $2,795 |
| Flecainide Acetate | 62 | $2,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $141 | $762,577612 claims |
| Boehringer IngelheimJardiance | $154 | $123,569109 claims |
| NovartisEntresto | $19 | $99,38576 claims |
| Johnson & JohnsonXarelto | $249 | $98,64491 claims |
| Sanofi-aventis U.S. LLCMultaq | $257 | $43,50126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in E Palo Alto
- Melissa KongE Palo Alto$303K
- Robert MeadE Palo Alto$184K
- Shephal DoshiSanta Monica$2.1M
- Jonathan HsuSan Diego$1.2M
- Leslie SaxonLos Angeles$1.1M
- Rahul BhardwajLoma Linda$935K
- Nicholas Olsonla Jolla$801K
- Jonathan DukesVentura$775K
- Brett GidneySanta Barbara$756K
- John Rogersla Jolla$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.